Echocardiography image is courtesy of Dr. Linda Gillam, Atlantic Health System, Morristown, NJ. Individual results may vary.
*Ultrasound Enhancing Agent
Having access to LUMASON, which does not require special equipment, has allowed us to continue to utilize contrast when needed without additional equipment or staff that would otherwise bring an activated vial into an isolation room.
The individuals who appear are for illustrative purposes. All persons depicted are models and not real patients or healthcare professionals.
Having the convenience of everything I need in a single kit to administer quickly means I can spend more time focusing on the patient.
The individuals who appear are for illustrative purposes. All persons depicted are models and not real patients or healthcare professionals.
I never realized how much time I spent getting the refrigerated agent from storage, finding the mixer and reconstituting – I guess we never knew we had other options?
Very low MI techniques produce high quality signal-to-noise ratios giving you the ability to be visually decisive.
The individuals who appear are for illustrative purposes. All persons depicted are models and not real patients or healthcare professionals.
Echocardiography images are courtesy of Dr. Linda Gillam, Atlantic Health System, Morristown, NJ. Individual results may vary.
Learning to recognize your segments in 4-chamber, 2-chamber and 3-chamber apical views quickly is the foundation for becoming a Great Sonographer.
Echocardiography images are courtesy of Dr. Linda Gillam, Atlantic Health System, Morristown, NJ. Individual results may vary.
Patient’s experiencing back pain doesn’t just increase the time it takes to complete the study, it impacts patient satisfaction.
The individual who appears is for illustrative purposes. The person depicted is a model and not a real patient.
LUMASON® ultrasound enhancing agent was administered 2,137 times with no reports of back pain.7*
* Based on a single-center study of adult patients (age >18 years) receiving a UEA (LUMASON®, Optison™, or Definity®) were prospectively evaluated for clinically significant adverse events defined as either anaphylactoid reactions (rash, flank pain, dyspnea, and wheeze) or true anaphylaxis. Study objectives included the following: determining the major adverse reactions experienced by patients receiving UEA in a clinical setting, assessing whether microbubbles are safe for use in patients with intra-cardiac shunts, and assessing whether the types of adverse reactions differ significantly among the three FDA-approved UEAs.
There’s only one agent we trust for our pediatric patients.
The individuals who appear are for illustrative purposes. All persons depicted are models and not real patients or healthcare professionals.
Dr. Stephanie Wilson
LUMASON is the only UEA approved for pediatric patients.3
There’s only one agent we trust for our pediatric patients.
The individual who appears is for illustrative purposes. The person depicted is a model and not a real patient.
We are looking for a large number of biomedical applications, and are confident that our technology can be used to address a wide range of healthcare challenges, for the best of patient care.
The Geneva Center, Bracco Research SA.
The individuals who appear are for illustrative purposes. All persons depicted are models and not real healthcare professionals.
LUMASON® (sulfur hexafluoride lipid-type A microspheres) for injectable suspension, for intravenous use or intravesical use
Indications
LUMASON® (sulfur hexafluoride lipid-type A microspheres) for injectable suspension, for intravenous use or intravesical use is an ultrasound contrast agent indicated for use:
IMPORTANT SAFETY INFORMATION
WARNING: SERIOUS CARDIOPULMONARY REACTIONS
Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following the injection of ultrasound contrast agents, including sulfur hexafluoride lipid microspheres. Most serious reactions occur within 30 minutes of administration.
Contraindications
LUMASON (sulfur hexafluoride lipid-type A microspheres) for injectable suspension, for intravenous use or intravesical use is contraindicated in patients with known or suspected hypersensitivity to sulfur hexafluoride lipid microsphere or its components, such as polyethylene glycol (PEG).
Warnings
Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or shortly following administration of ultrasound contrast agents, including LUMASON. Always have cardiopulmonary resuscitation personnel and equipment readily available prior to LUMASON administration and monitor all patients for acute reactions.
Post-marketing hypersensitivity reactions, including serious hypersensitivity reactions, have been observed during use or shortly following LUMASON administration. These reactions may occur in patients with no history of prior exposure to sulfur hexafluoride lipid-containing microspheres. LUMASON contains PEG. There may be increased risk of serious reactions including death in patients with prior hypersensitivity reaction(s) to PEG.
Systemic embolization may occur in patients with cardiac shunts. Assess patients with cardiac shunts for embolic phenomena following LUMASON administration.
There is a risk of ventricular arrhythmia related to high mechanical index in patients administered LUMASON. LUMASON is not recommended for use at mechanical indices greater than 0.8.
The most common adverse reactions (incidence ≥ 0.5%) are headache (1%) and nausea (0.5%).
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Please click here for full Prescribing Information for LUMASON ultrasound contrast agent, including BOXED WARNING on Serious Cardiopulmonary Reactions.
LUMASON is manufactured for Bracco Diagnostics Inc., Monroe Township, NJ 08831 by Bracco Suisse S.A., Plan-les-Ouates Geneve, Switzerland (LUMASON lyophilized powder vial-25 mg lipid-type A/60.7 sulfur hexafluoride gas); Vetter Pharma-Fertigung GmbH & Co. KG, 88212 Ravensburg, Germany (Sodium Chloride 0.9% Injection, USP); B. Braun Melsungen AG, 34212 Melsungen, Germany (Mini-Spike).
LUMASON is a registered trademark of Bracco Diagnostics Inc.
Bracco Diagnostics Inc.
259 Prospect Plains Road, Building H
Monroe Township, NJ 08831 USA
Phone: 609-514-2200
Toll Free: 1-877-272-2269 (U.S. only)
Fax: 609-514-2446
© 2022 Bracco Diagnostics Inc. All Rights Reserved. US-LUM-2000052 06/21
IMPORTANT SAFETY INFORMATION | INDICATIONS AND USAGE
LUMASON® (sulfur hexafluoride lipid-type A microspheres) for injectable suspension, for intravenous use or intravesical use
IMPORTANT SAFETY INFORMATION
WARNING: SERIOUS CARDIOPULMONARY REACTIONS
Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following the injection of ultrasound contrast agents, including sulfur hexafluoride lipid microspheres. Most serious reactions occur within 30 minutes of administration.